Genetic and epigenetic markers in the evaluation of pancreatic masses
- 7 November 2012
- journal article
- Published by BMJ in Journal of Clinical Pathology
- Vol. 66 (3) , 192-197
Abstract
Background: Methylation markers have shown promise in the early diagnosis of pancreatic carcinoma. The aim of this study was to assess the diagnostic utility of hypermethylation status of candidate genes in combination with KRAS mutation detection in the evaluation of pancreatic masses. Experimental design: Sixty-one fine needle aspirates of pancreatic masses (43 pancreatic adenocarcinomas and 18 chronic pancreatitis) were studied. Methylation status of HRH2, EN1, SPARC, CDH13 and APC were analysed using melting curve analysis after DNA bisulfite treatment. KRAS mutations were also analysed. Results: The methylation panel had a sensitivity of 73% (27 of 37, CI 95% 56 to 86%) and a specificity of 100% whenever two or more promoters were found hypermethylated. KRAS mutations showed a sensitivity of 77% (33 of 43, CI 95% 62 to 88%) and a specificity of 100%. Both molecular analyses added useful information to cytology by increasing the number of informative cases. When genetic and epigenetic analyses were combined sensitivity was 84% (36 of 43 CI 95% 69 to 93%) maintaining a 100% specificity. Conclusions: Analysis of hypermethylation status of a panel of genes and KRAS mutation detection offer a similar diagnostic yield in the evaluation of pancreatic masses. The combined molecular analysis increases the number of informative cases without diminishing specificity.Keywords
This publication has 25 references indexed in Scilit:
- Stool DNA testing for the detection of pancreatic cancerCancer, 2011
- Long-range epigenetic silencing at 2q14.2 affects most human colorectal cancers and may have application as a non-invasive biomarker of diseaseBritish Journal of Cancer, 2009
- CpG island methylation profile of pancreatic intraepithelial neoplasiaLaboratory Investigation, 2007
- Aberrant methylation of Reprimo correlates with genetic instability and predicts poor prognosis in pancreatic ductal adenocarcinomaCancer, 2006
- Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome bandNature Genetics, 2006
- SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor–stromal interactionsOncogene, 2003
- Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinomaOncogene, 2003
- Prospective evaluation of the contribution of K-ras mutational analysis and CA 19.9 measurement to cytological diagnosis in patients with clinical suspicion of pancreatic cancerEuropean Journal of Cancer, 2000
- The potential diagnostic use of K-ras codon 12 andp53 alterations in brush cytology from the pancreatic head regionThe Journal of Pathology, 1998
- Diagnostic utility of K-ras mutations in fine-needle aspirates of pancreatic massesGastroenterology, 1996